Sequence 15 from Patent US 20200079827

General Information


DRACP ID  DRACP01512

Peptide Name   Sequence 15 from Patent US 20200079827

Sequence  LKKWWKKVKGLLGGLLGKVTSVIK

Sequence Length  24

UniProt ID  Not available

PubChem CID  Not available

Origin  Synthetic construct

Type  Synthetic peptide

Classification

  

Active ACP



Activity Information


Hemolytic Activity  Not available

Normal (non-cancerous) Cytotoxicity  Not available

Target  Not available

Affinity  Not available

Mechanism  Not available

Nature  Anticancer; Antimicrobial



Structure Information


PDB ID  Not available

Predicted Structure  DRACP01512

Helicity  Not available

Linear/Cyclic  Not available

Disulfide/Other Bond  Not available

N-terminal Modification  Not available

C-terminal Modification  Not available

Other Modification  None

Chiral  L



Physicochemical Information


Formula  C130H223N33O27

Absent amino acids  ACDEFHMNPQRY

Common amino acids  K

Mass  309085

Pl  11.58

Basic residues  7

Acidic residues  0

Hydrophobic residues  11

Net charge  7

Boman Index  524

Hydrophobicity  16.25

Aliphatic Index  133.75

Half Life 
  Mammalian: 5.5 hour
  Yeast: 3 min
  E.coli: 2 min

Extinction Coefficient cystines  11000

Absorbance 280nm  478.26

Polar residues  6

Amino acid distribution



Literature Information


Literature 1

Pubmed ID Not available

Title  Not available

Doi Not available

Year  Not available

Patent

Patent ID US 2020/0079827 A1

Patent Title  Novel Antimicrobial And Anti-cancer Therapy

Other Iinformation  Granted Patent Family: 6s / 6ex; Family Jurisdictions: EP, IL, AU, US, AT, DEUS, EP, CN, WO; Legal Status: Active; Application No: 201716462586; Filed:Nov 21, 2017; Published: Mar 12, 2020; Earliest Priority: Nov 21, 2016; Granted: Mar 29, 2022

Other Published ID  WO2018094403A1  CN109996554A  EP3541405A1  EP3541405A4 




DRACP is developed by Dr.Zheng's team.